美女免费一级视频在线观看

Roche became the latest drugmaker to make a multibillion dollar pledge to invest in U.S. manufacturing, announcing a $50 billion investment over the next five years on Tuesday morning.

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

As part of the multiyear plan, Roche said it would strengthen its 13 manufacturing sites along with its 15 R&D sites across the country.

The company said it will support new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California as well as an additional site location to be announced soon.

The drugmaker predicted the investment would produce more than 12,000 new jobs in total — bringing its total U.S. workforce to 25,000 full-timers.

In a release unveiling the investment, Roche noted the geopolitical factors that provide context to the announcement. 

“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” Roche Group CEO Thomas Schinecker said in a statement. “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

The company added that its diagnostics division currently has an export surplus from the U.S. to other countries. Roche claimed that once this investment is realized, it will export more medicines from the U.S. than it imports. 

This comes nearly three weeks after the Trump administration announced tariffs on numerous countries across the world, including several longstanding allies.

The policy move roiled the global financial markets and was altered days later to include a 90-day pause for implementation — except, most notably, for China.

In the period since the tariffs were introduced, Trump and Commerce Secretary Howard Lutnick have suggested that tariffs specifically for the pharmaceutical industry will be unveiled within a month or two. 

During a closed-door meeting in February, Trump threatened the CEOs of several major drugmakers — including Merck, Pfizer and Eli Lilly — with tariffs if they didn’t move more of their manufacturing to the U.S.

Roche joins the list of major drugmakers who have taken proactive steps to bolster their domestic manufacturing capabilities in light of potential tariffs on the global supply chain.

Coincidentally, Regeneron announced plans to invest over $3 billion to boost U.S. manufacturing on Tuesday morning as well.

In late March, just days before the initial tariffs were unveiled, Johnson & Johnson announced it would spend $55 billion to develop new manufacturing facilities in the U.S. over the next four years.

Lilly recently announced it would spend $27 billion on U.S. manufacturing, commencing with building plans on four domestic manufacturing plants this year.

Additionally, Pfizer CEO Albert Bourla said his company would be prepared to move its international manufacturing operations to the U.S. if tariffs are imposed.

To read a May 2025 article on BMS planning a $40B U.S. investment as Trump signs an order to boost domestic pharma manufacturing, click here.